Semaglutide vs Tirzepatide: What the Research Says
Semaglutide and tirzepatide are the two names that dominate any talk of weight-loss medication. And the question I hear most is the obvious one: which is better? The semaglutide vs tirzepatide question is a fair one, but it has a more careful answer than most headlines give it. As a physiotherapist who reads this research closely, my goal here is simple. I want to show you what the head-to-head studies actually found, and, just as importantly, what they didn’t. That way, you can walk into a conversation with a clinician genuinely informed.
Semaglutide vs Tirzepatide: Two Different Molecules
Before we compare numbers, one difference matters: the two drugs don’t work in quite the same way. Both are GLP-1 receptor agonists, a mouthful that simply means they copy the gut hormone GLP-1. They calm your appetite through specific brain circuits, and they slow how fast your stomach empties. (I’ve explained that shared mechanism, step by step, in my article on how these medications act at a cellular level.)
Here’s the key difference. Semaglutide flips one switch, the GLP-1 receptor. Tirzepatide flips two: the GLP-1 receptor, plus a second one called GIP.1 That extra switch is the leading explanation for why tirzepatide’s trial numbers run higher. Working two systems at once seems to produce a bigger effect than working just one.1 Whether that means a better result for any one person is a separate question, and we’ll get to it.
What the Head-to-Head Trial Showed
For years, comparing the two was guesswork. Semaglutide’s STEP trials and tirzepatide’s SURMOUNT trials enrolled different people under different conditions. So lining up their numbers side by side was suggestive at best. That changed with SURMOUNT-5, the first trial to test them directly against each other, published in The New England Journal of Medicine in 2025.
| Measure | Tirzepatide | Semaglutide |
|---|---|---|
| Average weight lost (72 weeks)2 | 20.2% | 13.7% |
| Trial design | Randomised, head-to-head; 751 adults with obesity, without diabetes2 | |
SURMOUNT-5 enrolled 751 adults with obesity but without diabetes. Each person took the highest dose they could comfortably tolerate, and the trial followed them for 72 weeks.2 Tirzepatide led to an average weight loss of 20.2%, versus 13.7% for semaglutide, a real and statistically solid gap.2 These numbers also line up with each drug’s original trials: STEP 1 reported 14.9% for semaglutide,3 and SURMOUNT-1 reported up to 20.9% for tirzepatide.4
What the Numbers Don’t Tell You
In any semaglutide vs tirzepatide comparison, this is the part I most want you to take away, because it’s where oversimplified head-to-heads do real harm. The weight-loss percentage is just one factor among several. And the trial average says nothing about the ones that actually decide the right choice for you:
| Factor | Why it matters for the choice |
|---|---|
| How well you tolerate it | Both can upset your stomach. Which one sits better with you varies, and the drug you tolerate best is often the one that works best for you. |
| Your personal response | Trial averages hide a huge spread. Some people respond strongly to semaglutide and only mildly to tirzepatide, or the other way around. |
| Your medical history | Other health conditions, medications, and heart-and-metabolism risk factors all affect which drug a clinician thinks is right for you. |
| Heart-health track record | The two drugs have different bodies of evidence on heart outcomes. A clinician weighs that against your own risk. |
| What happens to your muscle | Both take some muscle along with fat. What you do alongside either, training, protein, matters more here than the choice between them. |
That last row is where my physiotherapy lens comes in hardest. Arguing over which drug loses an extra few percent, while ignoring whether that loss costs you muscle, misses the bigger variable. Whichever drug you end up on, the muscle-protection playbook is the same, I cover it in my piece on GLP-1 and muscle loss.
One More Thing: The Product Behind the Molecule
One thing gets lost in most “semaglutide vs tirzepatide” debates. The trial numbers above come from the FDA-approved branded products, tested under tight, controlled conditions. That’s not automatically the same as a compounded version of these molecules, which raises its own separate questions about rules and quality. Curious how these medications are actually obtained, and what “compounded” really means? I’ve written a dedicated explainer on the compounding rules and what they mean. Because the molecule and the product you actually receive aren’t always the same thing.
The Bottom Line
Here’s my honest read. In a head-to-head semaglutide vs tirzepatide trial, the evidence points to tirzepatide producing more average weight loss, and its two-switch design offers a believable reason why.1,2 If raw average results were all that mattered, that would settle it. But they aren’t. How well you tolerate the drug, how your body responds, your medical history, what you do alongside it, all of it shapes the real-world outcome. And none of that shows up in a headline percentage.
So the useful takeaway isn’t “pick tirzepatide.” It’s that this is a medical decision, not a shopping one. The right call belongs with a qualified prescriber who can weigh your specific situation. If a program or provider treats the choice as a no-brainer, either way, without assessing you first, that itself tells you something.
As always, this is educational information and not medical advice.
- GLP-1 and GIP receptor signalling in beta cells; tirzepatide dual-agonist mechanism and biased GLP-1R signalling. ScienceDirect S0196978122000158.
- SURMOUNT-5: head-to-head tirzepatide vs semaglutide, 751 adults, 72 weeks. N Engl J Med. 2025.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989 to 1002.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205 to 216.
This article is for educational purposes only and does not constitute medical advice. It does not recommend or endorse any specific medication and is not sponsored. Decisions about GLP-1 therapy should be made with a qualified healthcare professional. Figures are drawn from the referenced primary literature.